, Tracking Stock Market Picks
Enter Symbol:
Rating: PRXL
Neutral $63

Parexel International Corporation (NASDAQ: PRXL) downgraded to Neutral with price target $63 by Robert W. Baird

Thursday,  Oct 30, 2014  8:25 AM ET by Kristen Bailey

Robert W. Baird downgraded Parexel International Corporation (NASDAQ: PRXL) to Neutral with
price target $63. Robert W. Baird rated Parexel International Corporation (NASDAQ: PRXL) to Outperform with price target $64 on 06/26/2014, when the price was $53.12.

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy